Medy-Tox Inc (086900) — Capital Reinvestment Ratio
Medy-Tox Inc (086900) has a Capital Reinvestment Ratio of 0.34x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩19.03 Billion) in capital expenditures (₩6.46 Billion). See Medy-Tox Inc balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Medy-Tox Inc Capital Reinvestment Ratio (2013–2024)
This chart tracks Medy-Tox Inc's Capital Reinvestment Ratio across 12 annual periods. Check 086900 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Medy-Tox Inc (2013–2024)
Year-by-year Capital Reinvestment Ratio for Medy-Tox Inc from 2013 to 2024. For live market cap and broader valuation context, see Medy-Tox Inc (086900) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.51x | ₩36.89 Billion | ₩18.72 Billion | ▼ -81.7% |
| 2023 | 2.77x | ₩13.52 Billion | ₩37.47 Billion | ▲ +633.7% |
| 2022 | 0.38x | ₩26.20 Billion | ₩9.90 Billion | ▼ -56.9% |
| 2021 | 0.88x | ₩19.97 Billion | ₩17.51 Billion | ▼ -40.5% |
| 2020 | 1.47x | ₩27.93 Billion | ₩41.14 Billion | ▲ +136.2% |
| 2019 | 0.62x | ₩33.70 Billion | ₩21.02 Billion | ▲ +304.2% |
| 2018 | 0.15x | ₩55.07 Billion | ₩8.50 Billion | ▼ -77.1% |
| 2017 | 0.67x | ₩56.55 Billion | ₩38.04 Billion | ▼ -74.8% |
| 2016 | 2.67x | ₩54.10 Billion | ₩144.67 Billion | ▲ +76.9% |
| 2015 | 1.51x | ₩22.37 Billion | ₩33.81 Billion | ▲ +857.5% |
| 2014 | 0.16x | ₩105.38 Billion | ₩16.64 Billion | ▼ -84.2% |
| 2013 | 1.00x | ₩16.60 Billion | ₩16.55 Billion | — |